Meeting
2020 ASCO Virtual Scientific Program
Molecular correlates of response to preoperative olaparib alone or with cisplatin or with durvalumab in head and neck squamous cell carcinoma (HNSCC): A Hellenic Cooperative Oncology Group study.
Authors
Amanda Psyrri
Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
Amanda Psyrri , George Papaxoinis , Niki Gavrielatou , Maria Gkotzamanidou , Panagiota Economopoulou , Ioannis Kotsantis , Aris Spathis , Maria Anastasiou , Stavros Gkolfinopoulos , Martha Nifora , George Fountzilas , Periklis Foukas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02882308
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6556)
DOI
10.1200/JCO.2020.38.15_suppl.6556
Abstract #
6556
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC).
First Author: Amanda Psyrri
Poster
2017 ASCO Annual Meeting
Phase II (window) preoperative study of olaparib with cisplatin or with durvalumab or alone or no treatment in patients with histologically proven head and neck squamous cell carcinoma who are candidates for surgery (OPHELIA).
First Author: Amanda Psyrri
Poster
2020 ASCO Virtual Scientific Program
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.
First Author: Sarah Verhoeff
Poster
2020 ASCO Virtual Scientific Program
Genomic landscape and immune phenotype of malignant pleural mesothelioma.
First Author: Meera Patel